Aggressive periodontitis: An appraisal of systemic effects on its etiology-genetic aspect

Kundu Debabrata1, Bandyopadhyay Prasanta1, Nair Vineet1

  • 1Department of Periodontia, Dr. R. Ahmed Dental College and Hospital, Kolkata, India.

Abstract

Insights

Myeloperoxidase (MPO) gene polymorphism may increase aggressive periodontitis (AP) risk. Telomerase (hTERT) expression is significantly elevated in AP tissues compared to chronic periodontitis (CP) and healthy controls.

Area of Science:

  • Genetics and Molecular Biology
  • Oral and Dental Medicine
  • Immunology

Background:

  • Myeloperoxidase (MPO) mediates inflammatory tissue destruction in periodontitis.
  • Human telomerase (hTERT) is implicated in inflammatory conditions, including periodontitis.
  • Investigating MPO gene polymorphism and telomerase expression in aggressive periodontitis (AP) is crucial.

Purpose of the Study:

  • To explore the role of MPO-463G/A gene polymorphism in aggressive periodontitis (AP) subjects.
  • To determine the level of telomerase expression in AP subjects.
  • To compare these parameters with chronic periodontitis (CP) and healthy controls.

Main Methods:

  • Study included 45 subjects (15 healthy, 15 CP, 15 AP) aged 20-50.
  • Peripheral blood and gingival tissue samples were collected.
  • MPO gene polymorphism and telomerase expression detected via reverse transcriptase polymerase chain reaction.

Main Results:

  • AG and AA genotypes of MPO gene polymorphism were more frequent in AP subjects.
  • Telomerase (hTERT) mRNA expression was undetectable in healthy controls.
  • hTERT expression was significantly higher in AP (104.27 ± 6.06) than in CP (83.61 ± 2.94) subjects (P < 0.0001).

Conclusions:

  • MPO-463G/A gene polymorphism may be associated with an increased risk of aggressive periodontitis.
  • Elevated tissue hTERT levels were observed in AP subjects compared to CP and healthy controls.

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
125
The Oral Microbiota01:27

The Oral Microbiota

The oral microbiome includes a complex ecosystem comprising over 700 microbial species, identified through genomic sequencing and culture-based analyses to date. This community includes a core microbiome, found universally among individuals, and a variable component influenced by environmental factors such as diet, lifestyle, and host genetics. Site-specific conditions, including oxygen gradients, pH levels, and nutrient availability, determine the spatial distribution of these microorganisms...
52
Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
880
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
5.2K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
69
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
91